Capital Fund Management S.A. Acquires Shares of 20,707 Mallinckrodt PLC (MNK)
Capital Fund Management S.A. acquired a new stake in shares of Mallinckrodt PLC (NYSE:MNK) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 20,707 shares of the company’s stock, valued at approximately $386,000.
A number of other hedge funds have also modified their holdings of the stock. Van ECK Associates Corp increased its holdings in Mallinckrodt by 14.2% during the second quarter. Van ECK Associates Corp now owns 147,817 shares of the company’s stock valued at $2,758,000 after buying an additional 18,353 shares during the period. Commonwealth Bank of Australia increased its holdings in Mallinckrodt by 1,572,207.7% during the second quarter. Commonwealth Bank of Australia now owns 204,400 shares of the company’s stock valued at $3,811,000 after buying an additional 204,387 shares during the period. Credit Agricole S A purchased a new position in Mallinckrodt during the second quarter valued at approximately $1,268,000. Dimensional Fund Advisors LP increased its holdings in Mallinckrodt by 8.5% during the second quarter. Dimensional Fund Advisors LP now owns 4,422,787 shares of the company’s stock valued at $82,531,000 after buying an additional 345,385 shares during the period. Finally, Chicago Equity Partners LLC purchased a new position in Mallinckrodt during the second quarter valued at approximately $575,000.
NYSE:MNK opened at $29.67 on Tuesday. Mallinckrodt PLC has a 12 month low of $11.65 and a 12 month high of $39.05. The company has a debt-to-equity ratio of 0.98, a current ratio of 2.27 and a quick ratio of 2.06. The firm has a market cap of $2.66 billion, a PE ratio of 4.07, a P/E/G ratio of 0.53 and a beta of 1.57.
Several equities analysts recently issued reports on the stock. Berenberg Bank initiated coverage on shares of Mallinckrodt in a report on Friday. They set a “sell” rating and a $25.00 price objective on the stock. Goldman Sachs Group lowered shares of Mallinckrodt from a “neutral” rating to a “sell” rating and lifted their price target for the stock from $27.00 to $28.00 in a report on Tuesday, September 11th. Zacks Investment Research lowered shares of Mallinckrodt from a “buy” rating to a “hold” rating in a report on Thursday, September 6th. B. Riley lifted their price target on shares of Mallinckrodt from $20.00 to $37.00 and gave the stock a “neutral” rating in a report on Friday, August 24th. Finally, Wells Fargo & Co reaffirmed a “hold” rating on shares of Mallinckrodt in a report on Wednesday, August 22nd. Four equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $32.62.
Mallinckrodt public limited company develops, manufactures, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products.
Featured Article: Outstanding Shares
Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.